To address these issues, and to enable comparison of NfL with other proposed biomarkers, we have set up several multicentre MSA longitudinal studies (PROSPECT-M-UK, BIOPARK, IRAMS and ASPIRE-MSA) assessing biomarkers in association with clinical and neuroimaging outcomes. Here, NEFL is linked to multiple system atrophy.